<DOC>
	<DOCNO>NCT00880308</DOCNO>
	<brief_summary>This first-in-human dose-escalation study characterize safety , tolerability , pharmacokinetics pharmacodynamics LDE225 give orally daily dose schedule patient advance solid tumor .</brief_summary>
	<brief_title>Dose Finding Safety Oral LDE225 Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Basal Cell</mesh_term>
	<mesh_term>Medulloblastoma</mesh_term>
	<criteria>confirm diagnosis advance solid tumor ( include â€¢medulloblastoma basal cell carcinoma ) blood work criterion patient history brain tumor ( except recurrent medulloblastoma ) brain metastasis positive HIV , hepatitis B C impair intestinal function impair heart function pregnant breastfeeding woman Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Advanced tumor</keyword>
	<keyword>hedgehog</keyword>
	<keyword>smoothen inhibitor</keyword>
</DOC>